Stockscreener 앱 받기
4.33
0.23%
-0.010
전일 마감가:
$4.34
열려 있는:
$4.34
하루 거래량:
355.74K
Relative Volume:
2.17
시가총액:
$224.84M
수익:
$3.50M
순이익/손실:
$-80.40M
주가수익비율:
-1.6841
EPS:
-2.5711
순현금흐름:
$-29.83M
1주 성능:
-2.26%
1개월 성능:
-0.23%
6개월 성능:
-26.98%
1년 성능:
+181.17%
1일 변동 폭
$4.21
$4.505
1주일 범위
$4.005
$4.51
52주 변동 폭
$1.32
$7.75
Camp 4 Therapeutics Corp Stock (CAMP) Company Profile
명칭
Camp 4 Therapeutics Corp
전화
617-651-8867
주소
ONE KENDALL SQUARE, CAMBRIDGE, CA
Compare CAMP vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CAMP
Camp 4 Therapeutics Corp
|
4.33 | 224.84M | 3.50M | -80.40M | -29.83M | -2.5711 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Camp 4 Therapeutics Corp Stock (CAMP) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-14 | 개시 | Rodman & Renshaw | Buy |
| 2025-10-02 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-09-16 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2025-05-27 | 개시 | Wedbush | Outperform |
| 2024-11-05 | 개시 | JP Morgan | Overweight |
| 2024-11-05 | 개시 | Piper Sandler | Overweight |
| 2024-11-05 | 개시 | William Blair | Outperform |
| 2022-08-16 | 업그레이드 | Craig Hallum | Hold → Buy |
| 2021-12-22 | 다운그레이드 | Craig Hallum | Buy → Hold |
| 2021-09-24 | 재확인 | Craig Hallum | Buy |
| 2021-06-25 | 재확인 | Craig Hallum | Buy |
| 2020-12-18 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2020-04-17 | 업그레이드 | Jefferies | Hold → Buy |
| 2020-03-05 | 재확인 | Craig Hallum | Buy |
| 2019-12-20 | 재확인 | Craig Hallum | Buy |
| 2019-12-20 | 다운그레이드 | First Analysis Sec | Outperform → Neutral |
| 2019-06-28 | 업그레이드 | Northland Capital | Market Perform → Outperform |
| 2019-05-29 | 다운그레이드 | Goldman | Neutral → Sell |
| 2019-05-01 | 재확인 | Craig Hallum | Buy |
| 2019-03-25 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2019-01-25 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2018-12-21 | 업그레이드 | Craig Hallum | Hold → Buy |
| 2018-12-14 | 재확인 | B. Riley FBR | Buy |
| 2018-12-11 | 다운그레이드 | First Analysis Sec | Strong Buy → Outperform |
| 2018-12-11 | 다운그레이드 | Northland Capital | Outperform → Market Perform |
| 2018-11-27 | 개시 | Goldman | Neutral |
| 2018-10-15 | 개시 | Jefferies | Hold |
| 2018-09-28 | 재확인 | Craig Hallum | Hold |
| 2018-04-27 | 재확인 | Craig Hallum | Hold |
| 2018-03-08 | 다운그레이드 | Craig Hallum | Buy → Hold |
| 2018-02-16 | 업그레이드 | First Analysis Sec | Equal-Weight → Overweight |
모두보기
Camp 4 Therapeutics Corp 주식(CAMP)의 최신 뉴스
Is CAMP4 THERAPEUTICS CORPORATION (CAMP) Stock Undervalued Ahead of Key CMP-002 Clinical Development Milestones? - Yahoo Finance
X4 Pharmaceuticals appoints Kelly Gold to board of directors - Investing.com UK
X4 Pharmaceuticals appoints Kelly Gold to board of directors By Investing.com - Investing.com India
Camp4 Therapeutics Corporation(NasdaqGM: CAMP) added to Russell 2000 Index - marketscreener.com
Camp4 Therapeutics Corporation(NasdaqGM:CAMP) dropped from Russell Microcap Value Benchmark Index - marketscreener.com
Camp4 Therapeutics Corporation(NasdaqGM:CAMP) added to Russell 2000 Growth Benchmark - marketscreener.com
Camp4 Therapeutics Corporation(NasdaqGM:CAMP) added to Russell 3000E Growth Benchmark - marketscreener.com
Enterprise value to EBITDA forward of CAMP4 Therapeutics Corporation – NASDAQ:CAMP - TradingView
Enterprise value to EBITDA forward of CAMP4 Therapeutics Corporation – BOATS:CAMP - TradingView
Camp4 Therapeutics Corporation(NasdaqGM: CAMP) added to Russell 2500 Index - marketscreener.com
Enterprise value to EBIT forward of CAMP4 Therapeutics Corporation – NASDAQ:CAMP - TradingView
Enterprise value to revenue forward of CAMP4 Therapeutics Corporation – NASDAQ:CAMP - TradingView
Price to sales forward of CAMP4 Therapeutics Corporation – NASDAQ:CAMP - TradingView
CAMP Technical Analysis | Trend, Signals & Chart Patterns - ChartMill
Price to sales forward of CAMP4 Therapeutics Corporation – BOATS:CAMP - TradingView
Camp4 Therapeutics Corp advances industry and policy dialogue on orphan drug accessibility - Traders Union
CAMP4 Therapeutics Corp (CAMP) Valuation: PE, PB & Fair Value Analysis - TradingKey
CAMP4 Therapeutics Corporation Actuals & Estimates (NASDAQ:CAMP) - TradingView
CAMP Forecast — Price Target — Prediction for 2027 - TradingView
CAMP4 Therapeutics Q1 2026 Earnings: Wider-than-Expected Loss Weighs on Shares as Pre-Revenue Biotech Advances PipelineGuidance Downgrade Alert - dars.gov.et
Price to book forward of CAMP4 Therapeutics Corporation – NASDAQ:CAMP - TradingView
Positive Report for CAMP4 Therapeutics Corporation (CAMP) from J.P. Morgan - The Globe and Mail
CAMP4 Therapeutics Corp (CAMP) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Camp4 Therapeutics Corp advances regRNA therapy for SYNGAP1-related disorder after Nasdaq feature - Traders Union
CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
CAMPCAMP4 Therapeutics Corp Revenue Breakdown - Finviz
CAMP4 lures 3 new hires with 39,000 stock options - Stock Titan
CAMP4 Therapeutics Corp (CAMP) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
CAMP4 Therapeutics Corp (CAMP) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
CAMP4 Therapeutics Corp (CAMP) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
CAMP4 Therapeutics Corp (CAMP) Institutional Confidence - TradingKey
CAMP4 Therapeutics Corp (CAMP) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
CAMP4 Therapeutics Corp (CAMP) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
CAMP4 Therapeutics Corp (CAMP) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
W.P. Carey To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
This Exxon Mobil Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday - Benzinga
JPMorgan upgrades CAMP4 Therapeutics stock rating on CMP-002 potential - Investing.com
JPMorgan upgrades CAMP4 Therapeutics stock rating on CMP-002 potential By Investing.com - Investing.com Nigeria
CAMP4 Shareholders Approve Equity Plan Changes and Inducement Plan - The Globe and Mail
Camp4 Therapeutics (CAMP) director awarded 28,000 stock options - Stock Titan
Camp4 Therapeutics (CAMP) grants director 28,000 stock options - Stock Titan
Camp4 Therapeutics (CAMP) director granted options on 28,000 shares at $4.34 - Stock Titan
Camp4 Therapeutics director granted 28,000 options | CAMP Insider Trading - Stock Titan
Camp4 Therapeutics (CAMP) director awarded 28,000 stock options at $4.34 strike - Stock Titan
Camp4 Therapeutics director granted 28K options | CAMP Insider Trading - Stock Titan
CAMP4 Therapeutics (NASDAQ: CAMP) updates equity plans and elects Class II directors - Stock Titan
CAMP4 Therapeutics Corporation (CAMP) Receives a New Rating from Chardan Capital - The Globe and Mail
CAMP Initiated Coverage by Chardan Capital -- Rating Set to Buy - GuruFocus
Chardan initiates CAMP4 Therapeutics stock with buy rating - Investing.com UK
Chardan initiates CAMP4 Therapeutics stock with buy rating By Investing.com - Investing.com Australia
Camp 4 Therapeutics Corp (CAMP) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Camp 4 Therapeutics Corp 주식 (CAMP) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Polaris Management Co. VII, L. | 10% Owner |
Sep 11 '25 |
Buy |
1.53 |
1,307,189 |
1,999,999 |
2,825,500 |
| Nashat Amir | Director |
Sep 11 '25 |
Buy |
1.53 |
1,307,189 |
1,999,999 |
2,825,500 |
| Maricich Yuri | Chief Medical Officer |
Sep 11 '25 |
Buy |
1.65 |
6,060 |
9,999 |
6,060 |
| Gold Kelly | Chief Financial Officer |
Sep 11 '25 |
Buy |
1.65 |
6,060 |
9,999 |
67,877 |
| Mandel-Brehm Josh | Chief Executive Officer |
Sep 11 '25 |
Buy |
1.65 |
6,060 |
9,999 |
278,417 |
| Young Richard A | Director |
Sep 11 '25 |
Buy |
1.65 |
15,151 |
24,999 |
170,010 |
2.64%
자본화:
|
볼륨(24시간):